Literature DB >> 21779202

Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light.

Susanne Marschner1, Raymond Goodrich.   

Abstract

Bacterial contamination and emerging infections combined with increased international travel pose a great risk to the safety of the blood supply. Tests to detect the presence of infection in a donor have a 'window period' during which infections cannot be detected but the donor may be infectious. Agents and their transmission routes need to be recognized before specific tests can be developed. Pathogen reduction of blood components represents a means to address these concerns and is a proactive approach for the prevention of transfusion-transmitted diseases. The expectation of a pathogen reduction system is that it achieves high enough levels of pathogen reduction to reduce or prevent the likelihood of disease transmission while preserving adequate cell and protein quality. In addition the system needs to be non-toxic, non-mutagenic and should be simple to use. The Mirasol® Pathogen Reduction Technology (PRT) System for Platelets and Plasma uses riboflavin (vitamin B2) plus UV light to induce damage in nucleic acid-containing agents. The system has been shown to be effective against clinically relevant pathogens and inactivates leukocytes without significantly compromising the efficacy of the product or resulting in product loss. Riboflavin is a naturally occurring vitamin with a well-known and well-characterized safety profile. The same methodology is currently under development for the treatment of whole blood, making pathogen reduction of all blood products using one system achievable. This review gives an overview of the Mirasol PRT System, summarizing the mechanism of action, toxicology profile, pathogen reduction performance and clinical efficacy of the process.

Entities:  

Year:  2011        PMID: 21779202      PMCID: PMC3132976          DOI: 10.1159/000324160

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  67 in total

1.  In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology.

Authors:  Sisse R Ostrowski; Louise Bochsen; José A Salado-Jimena; Henrik Ullum; Inge Reynaerts; Raymond P Goodrich; Pär I Johansson
Journal:  Transfusion       Date:  2010-10-04       Impact factor: 3.157

Review 2.  Bacterial contamination of blood components.

Authors:  Mark E Brecher; Shauna N Hay
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

3.  Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light.

Authors:  L J Cardo; F J Rentas; L Ketchum; J Salata; R Harman; W Melvin; P J Weina; J Mendez; H Reddy; R Goodrich
Journal:  Vox Sang       Date:  2006-02       Impact factor: 2.144

Review 4.  Update on pathogen reduction technology for therapeutic plasma: an overview.

Authors:  B G Solheim; J Seghatchian
Journal:  Transfus Apher Sci       Date:  2006-08-24       Impact factor: 1.764

5.  Effect of riboflavin, retinol, and zinc on micronuclei of buccal mucosa and of esophagus: a randomized double-blind intervention study in China.

Authors:  N Muñoz; M Hayashi; L J Bang; J Wahrendorf; M Crespi; F X Bosch
Journal:  J Natl Cancer Inst       Date:  1987-10       Impact factor: 13.506

6.  An action spectrum of the riboflavin-photosensitized inactivation of Lambda phage.

Authors:  Christopher B Martin; Erin Wilfong; Patrick Ruane; Raymond Goodrich; Matthew Platz
Journal:  Photochem Photobiol       Date:  2005 Mar-Apr       Impact factor: 3.421

7.  Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates.

Authors:  Daniel R Ambruso; Gail Thurman; Susanne Marschner; Raymond P Goodrich
Journal:  Transfusion       Date:  2009-08-18       Impact factor: 3.157

8.  The influence of riboflavin photochemistry on plasma coagulation factors.

Authors:  Luis Larrea; María Calabuig; Vanesa Roldán; José Rivera; Han-Mou Tsai; Vicente Vicente; Roberto Roig
Journal:  Transfus Apher Sci       Date:  2009-09-25       Impact factor: 1.764

9.  Thiamine, riboflavin, folate, and vitamin B12 status of low birth weight infants receiving parenteral and enteral nutrition.

Authors:  R Levy; G R Herzberg; W L Andrews; B Sutradhar; J K Friel
Journal:  JPEN J Parenter Enteral Nutr       Date:  1992 May-Jun       Impact factor: 4.016

10.  Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction.

Authors:  S M Picker; L Oustianskaia; V Schneider; B S Gathof
Journal:  Vox Sang       Date:  2009-03-18       Impact factor: 2.144

View more
  48 in total

1.  Laboratory Evaluation of the Effectiveness of Pathogen Reduction Procedures for Bacteria.

Authors:  Thomas H Müller; Thomas Montag; Axel W Seltsam
Journal:  Transfus Med Hemother       Date:  2011-07-08       Impact factor: 3.747

2.  West nile virus.

Authors:  Georg Pauli; Ursula Bauerfeind; Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Thomas Montag-Lessing; Ruth Offergeld; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen
Journal:  Transfus Med Hemother       Date:  2013-07-04       Impact factor: 3.747

3.  Pathogen Reduction in Blood Products: What's Behind These Techniques?

Authors:  Karin Janetzko; Peter Bugert
Journal:  Transfus Med Hemother       Date:  2011       Impact factor: 3.747

4.  Introducing Pathogen Reduction Technology in Poland: A Cost-Utility Analysis.

Authors:  Maria Agapova; Elzbieta Lachert; Ewa Brojer; Magdalena Letowska; Piotr Grabarczyk; Brian Custer
Journal:  Transfus Med Hemother       Date:  2015-04-16       Impact factor: 3.747

5.  Antimicrobial blue light for decontamination of platelets during storage.

Authors:  Min Lu; TianHong Dai; SiSi Hu; Qi Zhang; Brijesh Bhayana; Li Wang; Mei X Wu
Journal:  J Biophotonics       Date:  2019-08-29       Impact factor: 3.207

Review 6.  Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology.

Authors:  Susan Yonemura; Suzann Doane; Shawn Keil; Raymond Goodrich; Heather Pidcoke; Marcia Cardoso
Journal:  Blood Transfus       Date:  2017-05-11       Impact factor: 3.443

Review 7.  Current methods for the reduction of blood-borne pathogens: a comprehensive literature review.

Authors:  Susanne M Picker
Journal:  Blood Transfus       Date:  2013-03-14       Impact factor: 3.443

8.  Treatment of buffy coat platelets in platelet additive solution with the mirasol(®) pathogen reduction technology system.

Authors:  Azucena Castrillo; Marcia Cardoso; Lindsay Rouse
Journal:  Transfus Med Hemother       Date:  2013-01-03       Impact factor: 3.747

Review 9.  Pathogen inactivation technologies for cellular blood components: an update.

Authors:  Peter Schlenke
Journal:  Transfus Med Hemother       Date:  2014-07-21       Impact factor: 3.747

10.  Comparison of UVA- and UVA/riboflavin-induced growth inhibition of Acanthamoeba castellanii.

Authors:  Karim Makdoumi; Anders Bäckman; Jes Mortensen; Anders Magnuson; Sven Crafoord
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-10-19       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.